Scope Fluidics has been awarded the title of Stock Exchange Company of the Year during the 7th Forbes Congress of Polish Capital, organised by Forbes Polska magazine. During the Congress gala, the award was presented by Forbes Poland magazine’s Editor-in-Chief to Gajane Żurawska – Scope Fluidics’ Global Business Development Director.
The title of Stock Exchange Company of the Year has been awarded for Scope Fluidics’ tremendous success with the sale of its PCR|ONE technology for a total of USD 170 million to the US company Bio-Rad Laboratories – a world leader in the field of bioanalytical techniques. The sale of the PCR|ONE technology demonstrates its global potential and provides Scope Fluidics with the basis for further dynamic growth.
We would like to thank the competition’s jury and the editors of Forbes Poland magazine for recognising our efforts in developing Polish innovative diagnostic technologies to be used in medicine.
“Can scientists build great companies? This was the question that Scope Fluidics’ investors posed when they lined up funding to create an ultrafast molecular diagnostic PCR device. To build it, Professor Piotr Garstecki and the team he created used microfluidic technology, which he had previously worked on as a scientist at Harvard, among other places”, writes Forbes Polska
As we read in Forbes Polska: “Their device can detect up to 20 viruses and bacteria, including Covid-19, in 20 minutes, doing so faster and more cheaply than the rival analysers from Roche or Abott. The Scope team have not only built it, but have also successfully commercialised it, selling PCR|ONE for USD 170 million and restoring faith in Polish innovations. And the stock market investors? Well, in four years they have made 1224 per cent on the company’s shares. We can only congratulate them!”
